Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: University of California, Davis
Condition: Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
NCT04587687
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.